Compare CoreWeave (CRWV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CoreWeave vs Merck & Co., Inc. — how do they compare? CoreWeave trades at $82.08 (market cap $44.99B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 7.8× CoreWeave's market cap, and Merck & Co., Inc. pays a 2.39% dividend while CoreWeave pays none. Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 7 Days and Merck & Co., Inc. for 98 Days on average.
| CRWV | MRK | |
|---|---|---|
Market Cap | $44.99B | $351.28B |
Volume | 41,993,776 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $143.08 | $156.43 |
52-Week Low | $60.82 | $82.49 |
Typical Hold Time | 7 Days | 98 Days |
Enterprise Value | $91.06B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRWV trades at $82.08, down 7.2% amid a broader AI stock sell-off. The technical picture is bearish, with price below key resistance levels. Fundamentally, the company shows strong revenue growth but deep losses, with a net income margin of -25.4% in 2026. A massive $104 billion backlog signals high demand, yet expansion requires significant debt and equity financing, increasing financial risk.
The outlook is polarized: high growth potential from AI infrastructure demand contrasts with substantial execution and financial risks. Analyst consensus is bullish with a $147.57 price target, but investors face volatility from debt-funded expansion and competitive pressures. The stock's trajectory hinges on converting its backlog to profitable revenue.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CoreWeave
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
